Man Group PLC Surface Oncology, Inc. Transaction History

Man Group PLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.62 - $1.21 $15,787 - $30,811	25,464 Added 190.03%	38,864 $31,000
Q3 2022 Nov 14, 2022	BUY	$1.05 - $2.1 $14,070 - $28,140	13,400 New	13,400 $14,000
Q2 2021 Aug 16, 2021	SELL	$6.45 - $9.09 $175,581 - $247,447	-27,222 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$7.25 - $13.82 $674,989 - $1.29 Million	-93,102 Reduced 77.38%	27,222 $212,000
Q4 2020 Feb 16, 2021	BUY	$6.87 - $10.48 $608,846 - $928,779	88,624 Added 279.57%	120,324 $1.11 Million
Q3 2020 Nov 16, 2020	BUY	$5.06 - $7.23 $160,402 - $229,191	31,700 New	31,700 $219,000
Q2 2019 Aug 14, 2019	SELL	$2.75 - $4.89 $156,714 - $278,666	-56,987 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$4.11 - $5.88 $325,544 - $465,743	-79,208 Reduced 58.16%	56,987 $272,000
Q3 2018 Nov 14, 2018	BUY	$8.92 - $17.83 $545,859 - $1.09 Million	61,195 Added 81.59%	136,195 $1.49 Million
Q2 2018 Aug 14, 2018	BUY	$12.83 - $17.41 $962,250 - $1.31 Million	75,000 New	75,000 $1.22 Million

315K

Ticker SURF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,034,000
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.